Anastro-Med, Anastrozole, 1 mg, 60 Tabs

Anastrozole 1 mg tablets by Bioniche Pharma are a potent third-generation non-steroidal aromatase inhibitor (AI) originally engineered for targeted oncological therapy in postmenopausal breast cancer. Formulated by Bioniche Pharma to suppress endogenous estrogen production, Bioniche Pharma Anastrozole is utilized in therapeutic protocols to manage hyperestrogenism and mitigate estrogenic complications secondary to aromatization.

Chemical Specifications & Regulatory Details:

• Active Substance: Anastrozole (1 mg per oral uncoated tablet)
• Molecular Formula & Weight: C₁₇H₁₉N₅ | 293.374 g/mol
• CAS Registry Number: 120511-73-1
• Drug Class & Category: Non-steroidal Aromatase Inhibitor (AI) | Prescription Only Medicine (POM)
• Packaging: Bottle containing 50 tablets

CLINICAL PHARMACOLOGY

Anastrozole in Bioniche Pharma Anastrozole selectively inhibits the aromatase enzyme complex responsible for converting adrenal and testicular androgens into estrogens. Clinical evaluations demonstrate that daily administration can reduce circulating serum estradiol levels by up to 80%. Secondary endocrine effects include a compensatory upregulation of pituitary Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) secretion, which can subsequently elevate total serum testosterone concentrations by up to 50% in male subjects.

INDICATIONS & CLINICAL USE

• Treatment of advanced or hormone receptor-positive breast carcinoma in postmenopausal women, including cases refractory to tamoxifen therapy using Bioniche Pharma formulations.
• Therapeutic management of male hypogonadism and estrogen-mediated hormonal imbalances under specialized physician direction.

DOSAGE & ADMINISTRATION

Administration protocols for Anastrozole 1 mg by Bioniche Pharma should be individually calculated based on baseline serum hormone profiles and clinical oversight:

• Male Patients: Typical therapeutic ranges vary from 0.5 mg to 3 mg daily. Due to its pharmacokinetic half-life, daily dosing is frequently divided into two to six equal administrations throughout the day to maintain stable plasma concentrations. Post-cycle recovery regimens typically begin at higher threshold doses before progressive downward titration over a 7- to 14-day duration.
• Female Patients: The standard recommended threshold is 1 mg per day to manage hyperestrogenism effectively using Bioniche Pharma Anastrozole.

CONTRAINDICATIONS

• Known hypersensitivity or allergic reaction to Anastrozole or compounding excipients (manifesting as anaphylaxis, angioedema, or severe urticaria).
• Pregnancy and nursing due to severe risks of fetal harm and teratogenicity.
• Premenopausal women presenting with breast cancer, where clinical efficacy and safety have not been established.

PRECAUTIONS & CARDIOVASCULAR RISK

• Ischemic Heart Disease: Clinical trial data (ATAC study) indicate an elevated incidence of ischemic cardiovascular events in patients with preexisting ischemic heart conditions (17% vs 10% in comparative arms). A careful risk-benefit evaluation is required prior to initiating Bioniche Pharma Anastrozole therapy.
• Lipid Profile Alterations: Associated with an increased incidence of elevated serum cholesterol concentrations relative to alternative therapies during Bioniche Pharma treatment.
• Bone Mineral Density: Profound estrogen suppression accelerates osteolytic bone resorption, increasing the risk of osteopenia, osteoporosis, and skeletal fractures (particularly of the spine, hip, and wrist). Periodic bone mineral density monitoring is advised during Bioniche Pharma therapy.
• Cognitive & Motor Impairment: May induce dizziness or somnolence. Caution is advised when operating machinery or driving, particularly if co-administered with alcohol or central nervous system depressants during treatment.

ADVERSE REACTIONS

Rare / Severe Reactions (<0.01% incidence):

• Severe dermatological conditions, including ulcerative skin lesions or bullous blistering.
• Systemic hypersensitivity causing angioedema of the face, lips, tongue, or pharynx, potentially leading to airway compromise or dysphagia.
• Hepatic toxicity, hepatitis, and transient transaminase elevations, with or without clinical jaundice or abdominal distress associated with Bioniche Pharma Anastrozole use.

Common Adverse Effects (~10% incidence):

• Vasomotor symptoms (hot flashes), asthenia, and fatigue reported during Bioniche Pharma Anastrozole therapy.
• Musculoskeletal pain, arthralgia, back pain, and joint stiffness.
• Cardiovascular and fluid balance disruptions, including hypertension and peripheral edema.
• Gastrointestinal upset (nausea, emesis), cephalalgia, insomnia, mood alterations/depression, pharyngitis, dyspnea, cutaneous rash, and lymphedema experienced by patients.

DRUG INTERACTIONS

• Warfarin: Clinical trials indicate no significant alteration in systemic exposure ($C_{max}$ or $AUC$) or clinical anticoagulant activity (PT, aPTT, TT) for either R- or S-enantiomers when co-administered with Bioniche Pharma